Abstract P5-11-14: Palbociclib in combination with anastrozole or exemestane as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study

Mapping Intimacies ◽

10.1158/1538-7445.sabcs19-p5-11-14 ◽

2020 ◽

Author(s):

Manfred Welslau ◽

Norbert Marschner ◽

Ulrike Söling ◽

Cosima Brucker ◽

Oliver J. Stoetzer ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Phase 2 ◽

First Line ◽

First Line Therapy ◽

Her2 Breast Cancer ◽

Line Therapy ◽

Phase 2 Study

Download Full-text

Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study

Cancer ◽

10.1002/cncr.30170 ◽

2016 ◽

Vol 122 (20) ◽

pp. 3119-3126 ◽

Cited By ~ 8

Author(s):

Jean-Marc Ferrero ◽

Anne-Claire Hardy-Bessard ◽

Olivier Capitain ◽

Alain Lortholary ◽

Bruno Salles ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Triple Negative ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Phase 2 ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study

Download Full-text

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-2923-9 ◽

2014 ◽

Vol 146 (2) ◽

pp. 321-328 ◽

Cited By ~ 32

Author(s):

Kristi McIntyre ◽

Joyce O’Shaughnessy ◽

Lee Schwartzberg ◽

Stefan Glück ◽

Erhan Berrak ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor Receptor ◽

Phase 2 ◽

First Line ◽

Eribulin Mesylate ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study ◽

Epidermal Growth ◽

Locally Recurrent

Download Full-text

Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study

Annals of Oncology ◽

10.1093/annonc/mdz100.007 ◽

2019 ◽

Vol 30 ◽

pp. iii50

Author(s):

A. Welt ◽

M.K. Welslau ◽

D. Lüftner ◽

M. Deryal ◽

R. Liersch ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Locally Advanced ◽

First Line ◽

First Line Therapy ◽

Her2 Breast Cancer ◽

Line Therapy

Download Full-text

Abstract CT139: First-line therapy with dacomitinib, an orally available pan-her tyrosine kinase inhibitor, for locally-advanced or metastatic penile squamous cell carcinoma: Results of an open label, single-arm, single-center, phase 2 study

10.1158/1538-7445.am2017-ct139 ◽

2017 ◽

Author(s):

Andrea Necchi ◽

Salvatore Lo Vullo ◽

Daniele Raggi ◽

Patrizia Giannatempo ◽

Nicola Nicolai ◽

...

Keyword(s):

Kinase Inhibitor ◽

Locally Advanced ◽

Phase 2 ◽

Single Center ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study ◽

Penile Squamous Cell Carcinoma

Download Full-text

Abstract P5-17-03: Quality of life results from a phase 2, multicenter, single-arm study of eribulin mesylate plus trastuzumab as first-line therapy for locally recurrent or metastatic HER2+ breast cancer

10.1158/1538-7445.sabcs14-p5-17-03 ◽

2015 ◽

Author(s):

Lee Schwartzberg ◽

Sharon Wilks ◽

Shannon Puhalla ◽

Joyce O'Shaughnessy ◽

Erhan Berrak ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Phase 2 ◽

First Line ◽

Eribulin Mesylate ◽

First Line Therapy ◽

Her2 Breast Cancer ◽

Line Therapy ◽

Locally Recurrent

Download Full-text

First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study

BJU International ◽

10.1111/bju.14013 ◽

2017 ◽

Vol 121 (3) ◽

pp. 348-356 ◽

Cited By ~ 30

Author(s):

Andrea Necchi ◽

Salvatore Lo Vullo ◽

Federica Perrone ◽

Daniele Raggi ◽

Patrizia Giannatempo ◽

...

Keyword(s):

Kinase Inhibitor ◽

Locally Advanced ◽

Phase 2 ◽

First Line ◽

Single Centre ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study ◽

Penile Squamous Cell Carcinoma

Download Full-text

1859 Clinical effects of prior chemotherapy on eribulin: Update and subgroup analysis of phase 2 multicenter single arm study of eribulin mesylate as first-line therapy for HER2 negative locally advanced or metastatic breast cancer

European Journal of Cancer ◽

10.1016/s0959-8049(16)30809-7 ◽

2015 ◽

Vol 51 ◽

pp. S285

Author(s):

S. Nishimura ◽

T. Takashima ◽

H. Kawajiri ◽

S. Kashiwagi ◽

S. Noda ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Clinical Effects ◽

Phase 2 ◽

First Line ◽

Eribulin Mesylate ◽

Prior Chemotherapy ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-3010-y ◽

2014 ◽

Vol 146 (2) ◽

pp. 329-329 ◽

Cited By ~ 1

Author(s):

Kristi McIntyre ◽

Joyce O’Shaughnessy ◽

Lee Schwartzberg ◽

Stefan Glück ◽

Erhan Berrak ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor Receptor ◽

Phase 2 ◽

First Line ◽

Eribulin Mesylate ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study ◽

Epidermal Growth ◽

Locally Recurrent

Download Full-text

Faculty Opinions recommendation of Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734230835.793559070 ◽

2019 ◽

Author(s):

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Preliminary Data ◽

Triple Negative ◽

Phase 2 ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study

Download Full-text

Abstract P1-19-30: Safety results from a phase 2 study of Palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer

10.1158/1538-7445.sabcs19-p1-19-30 ◽

2020 ◽

Author(s):

Oana C Danciu ◽

Kent Hoskins ◽

Cristina Truica ◽

Anne Blaes ◽

Deimante Tamkus ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Phase 2 ◽

First Line ◽

First Line Therapy ◽

Hormone Receptor Positive ◽

Line Therapy ◽

Phase 2 Study ◽

Positive Breast Cancer

Download Full-text